Selected article for: "harmful immune response and immune response"
Author: Farella, Ilaria; Panza, Raffaella; Capozza, Manuela; Laforgia, Nicola
Title: Lecithinized superoxide dismutase in the past and in the present: Any role in the actual pandemia of COVID-19?
  • Cord-id: xab82yyh
  • Document date: 2021_7_14
    • ID: xab82yyh
    Snippet: The Coronavirus disease 19 (Covid-19) pandemic is devastating the public health: it is urgent to find a viable therapy to reduce the multiorgan damage of the disease. A validated therapeutic protocol is still missing. The most severe forms of the disease are related to an exaggerated inflammatory response. The pivotal role of reactive oxygen species (ROS) in the amplification of inflammation makes the antioxidants a potential therapy, but clinical trials are needed. The lecitinized superoxide di
    Document: The Coronavirus disease 19 (Covid-19) pandemic is devastating the public health: it is urgent to find a viable therapy to reduce the multiorgan damage of the disease. A validated therapeutic protocol is still missing. The most severe forms of the disease are related to an exaggerated inflammatory response. The pivotal role of reactive oxygen species (ROS) in the amplification of inflammation makes the antioxidants a potential therapy, but clinical trials are needed. The lecitinized superoxide dismutase (PC-SOD) could represent a possibility because of bioaviability, safety, and its modulatory effect on the innate immune response in reducing the harmful consequences of oxidative stress. In this review we summarize the evidence on lecitinized superoxide dismutase in animal and human studies, to highlight the rationale for using the PC-SOD to treat COVID-19.

    Search related documents:
    Co phrase search for related documents
    • activation inflammation and acute infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • activation inflammation and acute renal failure: 1
    • activation inflammation and adhesion molecule: 1, 2, 3, 4
    • activation inflammation and adjunctive therapy: 1, 2
    • activation inflammation and long systemic: 1
    • activation inflammation and lung damage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • acute ards respiratory distress syndrome and adhesion molecule: 1, 2, 3, 4, 5, 6
    • acute ards respiratory distress syndrome and adjunctive therapy: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute ards respiratory distress syndrome and adjuvant treatment: 1, 2, 3, 4
    • acute ards respiratory distress syndrome and lung damage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ards respiratory distress syndrome development and lung damage: 1, 2, 3
    • acute infection and adhesion molecule: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • acute infection and adjunctive therapy: 1, 2, 3, 4, 5, 6, 7, 8
    • acute infection and adjuvant treatment: 1, 2, 3, 4, 5, 6
    • acute infection and long systemic: 1, 2, 3, 4, 5, 6
    • acute infection and lung damage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute renal failure and adjunctive therapy: 1, 2
    • acute renal failure and lung damage: 1, 2
    • adhesion molecule and lung damage: 1, 2